Amarin Corp Plc (AMRN)

[jessellivermore]

Re: SEs...

Sorry I can not agree with posters which minimize the importance of SEs. While it is true they might not be enough to side rail the trial: the facts are the pleotropic nature of EPA is such that V's potential therapeutic value extends way beyond merely being able to lower CVD event rates in patients with elevated trigs on statins.

Some of the SE's, I'm going to argue, are more important than the PEs.not from the trial design...we all understand the difference between PEs and SEs...but because for example, showing stat significance in lowering CVD event rates in T2DMs on statins is going to open up a richer market than "mixed dyslipidemia". Not because there are more diabetics, but because diabetics are more compliant..more attuned to being prescription dependent..

I have no opinion on whether the trial will be halted at this interim. I would not surprised in the least if it went to completion...

":>) JL